.png){kind=icon}
.png){kind=icon}
Return
How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?
.png){kind=icon}
OA
AI
A
D
J
A
S
P
J
T
A
A
DOI：10.1080/1750743X.2025.2571392.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
B-cell maturation antigen (BCMA) directed chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment of relapsed/refractory multiple myeloma (RRMM), yet relapse is still common for most patients. A variety of different salvage treatment strategies have been studied in the last several years to address several resistance mechanisms that lead to relapse after BCMA CAR-T. To date, there are no clear guidelines regarding treatment sequencing strategies for salvage therapy. This review will investigate the current landscape of available salvage therapies and data supporting their use, as well as possible treatment sequencing strategies to maximize clinical outcomes in this difficult-to-treat population.
Keywords:
Multiple myeloma
chimeric antigen receptor T-cells (CAR T-cells)
BCMA
GPRC5D
relapse
salvage therapy
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
J
IF:
2.9
Papers:
2.1K
Citations:
3.2K
Organization
Cited Papers